Claessen Femke M A P, Schol Ilse, Kolovich Gregory P, Ring David
Orthopaedic Hand and Upper Extremity Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
The University of Texas at Austin, Austin, TX, USA.
Arch Bone Jt Surg. 2020 Jan;8(1):94-98. doi: 10.22038/abjs.2019.39187.2047.
No consensus regarding optimal treatment or etiology of Preiser disease exists. We described the epidemiology, classification and treatment characteristics of 18 patients with Preiser disease. Patients with changes related to previous trauma, and without radiographs were excluded. Based on the radiographs at diagnosis, we classified 13 scaphoids as Herbert Lanzetta stage II, four as stage III, and one as stage IV. In 12 patients nonspecific treatment was offered and only two patients received surgical treatment. We found that chosen treatment is not associated with the severity of Herbert Lanzetta stage and the outcome is not influenced by chosen treatment.
关于Preiser病的最佳治疗方法或病因尚无共识。我们描述了18例Preiser病患者的流行病学、分类和治疗特点。排除有与既往创伤相关改变且无X光片的患者。根据诊断时的X光片,我们将13块舟骨分类为Herbert Lanzetta II期,4块为III期,1块为IV期。12例患者接受了非特异性治疗,只有2例患者接受了手术治疗。我们发现所选治疗方法与Herbert Lanzetta分期的严重程度无关,且治疗结果不受所选治疗方法的影响。